Aqilion runs four innovative programs

The Aqilion team and network has extensive expertise and experience in inflammation. The company runs four innovative R&D programs.

The Regulus program is the most advanced and Aqilion completed the first clinical study in humans in the summer of 2023. The Phase 1 ARIA-1 study aimed to evaluate the safety, tolerability, and pharmacokinetics of the drug candidate AQ280 in healthy adult participants. The preliminary study results are expected in Q4 2023. Aqilion has started preparations for a Phase 2a study in eosinophilic esophagitis patients, expected to start in 2024.

The Girtab program is in preclinical stage, while the Polaris program is in discovery phase.

The Alnitak program is in preclinical stage and will be developed together with Merck through a strategic research collaboration agreement, signed in February 2023.

All programs are based on the collective experience of the Aqilion team which allow us to make optimal use of the expertise of our network and partners.